ANIK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANIK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-25), Anika Therapeutics's current share price is $24.57. Anika Therapeutics's E10 for the quarter that ended in Mar. 2024 was $0.52. Anika Therapeutics's Shiller PE Ratio for today is 47.25.
The historical rank and industry rank for Anika Therapeutics's Shiller PE Ratio or its related term are showing as below:
During the past years, Anika Therapeutics's highest Shiller PE Ratio was 69.32. The lowest was 13.96. And the median was 34.16.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Anika Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.310. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.52 for the trailing ten years ended in Mar. 2024.
The historical data trend for Anika Therapeutics's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shiller PE Ratio | Get a 7-Day Free Trial | 22.22 | 21.03 | 16.09 | 34.03 | 48.96 |
For the Medical Instruments & Supplies subindustry, Anika Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Anika Therapeutics's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 24.57 | / | 0.52 | |
= | 47.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:
For example, Anika Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -0.31 | / | 131.7762 | * | 131.7762 | |
= | -0.310 |
Current CPI (Mar. 2024) = 131.7762.
Anika Therapeutics Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201406 | 0.600 | 100.560 | 0.786 |
201409 | 0.400 | 100.428 | 0.525 |
201412 | 0.510 | 99.070 | 0.678 |
201503 | 0.230 | 99.621 | 0.304 |
201506 | 0.510 | 100.684 | 0.667 |
201509 | 0.550 | 100.392 | 0.722 |
201512 | 0.720 | 99.792 | 0.951 |
201603 | 0.450 | 100.470 | 0.590 |
201606 | 0.570 | 101.688 | 0.739 |
201609 | 0.590 | 101.861 | 0.763 |
201612 | 0.540 | 101.863 | 0.699 |
201703 | 0.370 | 102.862 | 0.474 |
201706 | 0.760 | 103.349 | 0.969 |
201709 | 0.460 | 104.136 | 0.582 |
201712 | 0.530 | 104.011 | 0.671 |
201803 | -0.460 | 105.290 | -0.576 |
201806 | 0.680 | 106.317 | 0.843 |
201809 | 0.530 | 106.507 | 0.656 |
201812 | 0.540 | 105.998 | 0.671 |
201903 | 0.310 | 107.251 | 0.381 |
201906 | 0.670 | 108.070 | 0.817 |
201909 | 0.640 | 108.329 | 0.779 |
201912 | 0.280 | 108.420 | 0.340 |
202003 | 0.400 | 108.902 | 0.484 |
202006 | -0.540 | 108.767 | -0.654 |
202009 | -0.450 | 109.815 | -0.540 |
202012 | -1.100 | 109.897 | -1.319 |
202103 | 0.200 | 111.754 | 0.236 |
202106 | 0.450 | 114.631 | 0.517 |
202109 | 0.040 | 115.734 | 0.046 |
202112 | -0.400 | 117.630 | -0.448 |
202203 | -0.200 | 121.301 | -0.217 |
202206 | -0.200 | 125.017 | -0.211 |
202209 | -0.290 | 125.227 | -0.305 |
202212 | -0.340 | 125.222 | -0.358 |
202303 | -0.710 | 127.348 | -0.735 |
202306 | -0.190 | 128.729 | -0.194 |
202309 | -0.450 | 129.860 | -0.457 |
202312 | -4.300 | 129.419 | -4.378 |
202403 | -0.310 | 131.776 | -0.310 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Anika Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Anne Nunes | officer: SVP, Chief Operations Officer | 32 WIGGINS AVENUE, BEDFORD MA 01730 |
Gary P Fischetti | director | 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821 |
David Colleran | officer: EVP, General Counsel, Corp Sec | 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
Cheryl R Blanchard | director | C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580 |
Michael L Levitz | officer: EVP, CFO, Treasurer | C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960 |
Sheryl L Conley | director | C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355 |
Henneman John B Iii | director | 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
Raymond J Land | director | |
Stephen Richard | director | C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730 |
James Loerop | officer: EVP Business Development | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Sylvia Cheung | officer: CFO | ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730 |
Glenn R. Larsen | director | 32 WIGGINS AVENUE, BEDFORD MA 01730 |
Joseph I Bower | director | 32 WIGGINS AVENUE, BEDFORD MA 01730 |
Jeffery S Thompson | director | 1140 HAVENBROOK COURT, SUWANEE GA 30024 |
Joseph G Darling | officer: President | 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767 |
From GuruFocus
By Value_Insider Value_Insider • 10-25-2022
By Marketwired • 09-19-2023
By PRNewswire PRNewswire • 02-21-2023
By Marketwired • 07-12-2023
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 04-19-2023
By Marketwired • 08-17-2023
By PurpleRose PurpleRose • 07-12-2022
By PurpleRose PurpleRose • 07-12-2022
By GlobeNewswire GlobeNewswire • 07-12-2022